Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Shares Outstanding (Weighted Average) (2016 - 2025)

Fennec Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 15 years, with the latest figure at $28.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 4.7% year-over-year to $28.6 million, compared with a TTM value of $28.6 million through Dec 2025, up 4.7%, and an annual FY2025 reading of $28.6 million, up 4.7% over the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $28.6 million at Fennec Pharmaceuticals, up from $27.7 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $28.6 million in Q4 2025, with the low at $150000.0 in Q4 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $22.6 million, with a median of $26.5 million recorded in 2023.
  • Year-over-year, Shares Outstanding (Weighted Average) surged 66574.36% in 2021 and then crashed 99.45% in 2025.
  • Tracing FENC's Shares Outstanding (Weighted Average) over 5 years: stood at $26.0 million in 2021, then plummeted by 99.42% to $150000.0 in 2022, then changed by 0.0% to $150000.0 in 2023, then skyrocketed by 18096.0% to $27.3 million in 2024, then grew by 4.7% to $28.6 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Shares Outstanding (Weighted Average) are $28.6 million (Q4 2025), $27.7 million (Q3 2025), and $150000.0 (Q2 2025).